# Leal Health

> Leal Health (formerly TrialJectory) is an AI-powered treatment decision-support platform that gives cancer patients and their oncologists an unbiased, single point of access to FDA-approved therapies and clinical trials matched to a patient's exact diagnosis. Founded in 2017 and headquartered in New York, the company built a patented, generative-AI engine that reads thousands of trials and treatment options, then matches patients in a roughly two-minute intake. It has facilitated millions of treatment matches across 22+ cancer types, is free for patients and clinicians, and earns revenue from biopharma partners and health plans. In February 2026 Leal Health was acquired by Nexus Precision Health.

- **Founded:** 2017
- **Headquarters:** New York, New York, United States
- **Founders:** Tzvia Bader (CEO & Co-founder), Avital Gaziel (Co-founder), Noam Geva (Co-founder), Guy Gildor (Co-founder)
- **Team size:** ~18 employees
- **Products:** Patient treatment-matching platform, Oncologist matching portal, Single point of access to FDA-approved treatments, Program-level analytics platform, Generative-AI matching engine
- **Notable:** Named to TIME's 100 Best Inventions of 2020 (as TrialJectory), Honoree in the AI and data category of Fast Company's 2021 World-Changing Ideas Awards, Facilitated millions of cancer treatment matches (3M+ cited in 2026; 4M+ cited in some materials)

## Products & services

- **Patient treatment-matching platform** — A free, patient-facing AI tool where a person answers questions about their cancer diagnosis in roughly two minutes and receives matched FDA-approved treatments and clinical trials.
- **Oncologist matching portal** — A proprietary platform, free for oncologists, that surfaces personalized clinical-trial and treatment matches for their patients at the point of care.
- **Single point of access to FDA-approved treatments** — Positioned as the industry's first single point of access combining approved treatments and clinical trials for cancer patients.
- **Program-level analytics platform** — A patient-centric analytics product that helps pharmaceutical companies understand and improve patient participation in clinical trials.
- **Generative-AI matching engine** — A patented GenAI engine integrated into the platform to optimize the accuracy and speed of cancer treatment matching.
- **End-to-end patient support platform** — A next-generation offering to help cancer patients navigate their full treatment journey beyond the initial match.
- **Predictive patient-journey solution** — A predictive oncology solution that maps and anticipates the patient's likely treatment path.

## Achievements

- Named to TIME's 100 Best Inventions of 2020 (as TrialJectory)
- Honoree in the AI and data category of Fast Company's 2021 World-Changing Ideas Awards
- Facilitated millions of cancer treatment matches (3M+ cited in 2026; 4M+ cited in some materials)
- Built a patented generative-AI treatment-matching engine
- Covers 22+ cancer types, roughly 95% of cancers
- Acquired by Nexus Precision Health in February 2026

## Latest updates

- **2026-02** — Acquired by Nexus Precision Health; CEO Tzvia Bader joins the Nexus executive leadership team.
- **2024-05** — Launched a next-generation, end-to-end patient support platform to help patients navigate their full treatment journey.
- **2024-04** — Raised a Series B round (approx. $26M) to expand the AI treatment-matching platform.
- **2024-01** — Integrated generative-AI capabilities into the proprietary matching engine.
- **2023-06** — Launched a proprietary platform for oncologists to obtain personalized clinical-trial matches for patients.

## Links

- Website: https://leal.health
- LinkedIn: https://www.linkedin.com/company/lealhealth
- Twitter/X: https://twitter.com/TrialJectory
- Instagram: https://www.instagram.com/leal.health/
- Facebook: https://facebook.com/TrialJectory/

---

Profile page: https://yespress.io/leal-health
Published by YesPress — https://yespress.io
Last updated: 2026-07-19